Glucose Fresenius (Glucose Monohydrate)

Glucose Fresenius is employed in healthcare facilities primarily as a source of carbohydrate calories and as a diluent for intravenous drug preparations.

• Providing caloric support for patients unable to receive oral nutrition.
• Serving as a carrier solution for the reconstitution of powdered medications administered intravenously.
• Maintaining blood glucose levels during perioperative or critical‑care situations.
• Assisting in the management of hypoglycemia when administered under medical supervision.
• Facilitating fluid balance when combined with electrolytes in parenteral nutrition regimens.
• Diluting concentrated intravenous medications to achieve the desired infusion concentration.

Adverse reactions to Glucose Fresenius are generally related to the intravenous administration of a carbohydrate solution and may vary with infusion rate and patient condition.

Common

• Mild hyperglycemia when administered in large volumes.
• Local irritation or pain at the infusion site.
• Nausea or vomiting if the solution is infused rapidly.
• Electrolyte shifts such as mild hyponatremia when combined with other fluids.
• Transient increase in serum osmolality, usually self‑limited.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Hypersensitivity reactions including rash, urticaria, or anaphylaxis.
• Volume overload causing pulmonary edema in patients with compromised cardiac function.
• Metabolic acidosis in patients receiving large volumes without appropriate monitoring.

When using Glucose Fresenius, clinicians should observe several precautionary measures to ensure patient safety and optimal therapeutic outcomes.

• Verify patient’s baseline blood glucose and adjust infusion rate accordingly.
• Assess fluid balance and cardiac status to avoid volume overload.
• Use aseptic technique to prevent contamination of the intravenous solution.
• Monitor electrolytes, especially sodium and potassium, during prolonged infusions.
• Avoid rapid infusion rates that may cause hyperglycemia or osmotic shifts.
• Consider renal function, as impaired clearance can affect glucose handling.
• Document any adverse reactions promptly in the patient’s medical record.

Glucose Fresenius may interact with other intravenous therapies or medications; awareness of potential interactions helps prevent complications.

Avoid

• Co‑administration with high‑dose insulin infusions without proper monitoring, as it can precipitate severe hypoglycemia.
• Mixing with calcium‑containing solutions in the same line, which may cause precipitation.

Use with caution

• Concurrent use of diuretics that affect fluid balance; monitor for signs of volume overload.
• Administration alongside hypertonic saline or other hyperosmolar solutions; adjust infusion rates to avoid rapid shifts in serum osmolality.
• Use with beta‑adrenergic agonists that may increase glycogenolysis, potentially raising blood glucose levels.
• Patients receiving total parenteral nutrition; coordinate glucose delivery to match caloric needs.